{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:35:32Z","timestamp":1792751732808,"version":"4.5.0"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012001","name":"Al Jalila Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006013","name":"United Arab Emirates University","doi-asserted-by":"publisher","award":["AJF2018050"],"award-info":[{"award-number":["AJF2018050"]}],"id":[{"id":"10.13039\/501100006013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.lfs.2020.118054","type":"journal-article","created":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T21:27:12Z","timestamp":1594502832000},"page":"118054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Tackling the cytokine storm in COVID-19, challenges and hopes"],"prefix":"10.1016","volume":"257","author":[{"given":"Shifaa M.","family":"Abdin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shatha K.","family":"Alyammahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dima W.","family":"Alhamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany A.","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lfs.2020.118054_bb0005","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jmv.25678","article-title":"Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle","volume":"92","author":"Lu","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.lfs.2020.118054_bb0010","unstructured":"Organization WH. WHO director-general's remarks at the media briefing on 2019-nCoV on 11 February. https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. accessed 26 June, 2020."},{"issue":"10223","key":"10.1016\/j.lfs.2020.118054_bb0015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"10224","key":"10.1016\/j.lfs.2020.118054_bb0020","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2020.118054_bb0025","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1046\/j.1440-1843.2003.00518.x","article-title":"SARS: epidemiology","volume":"8","author":"Chan-Yeung","year":"2003","journal-title":"Respirology"},{"key":"10.1016\/j.lfs.2020.118054_bb0030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jtbi.2016.08.009","article-title":"A dynamic compartmental model for the Middle East respiratory syndrome outbreak in the Republic of Korea: a retrospective analysis on control interventions and superspreading events","volume":"408","author":"Lee","year":"2016","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.lfs.2020.118054_bb0035","unstructured":"World Health Organization W. Coronavirus disease (COVID-19) pandemic 2020. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019. accessed 26 June, 2020."},{"issue":"7798","key":"10.1016\/j.lfs.2020.118054_bb0040","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.lfs.2020.118054_bb0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"4","key":"10.1016\/j.lfs.2020.118054_bb0050","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"issue":"8","key":"10.1016\/j.lfs.2020.118054_bb0055","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2020.118054_bb0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coph.2017.12.002","article-title":"Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases","volume":"40","author":"Tan","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"issue":"7047","key":"10.1016\/j.lfs.2020.118054_bb0065","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.lfs.2020.118054_bb0070","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune responses","volume":"92","author":"Li","year":"2020","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.lfs.2020.118054_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000756","article-title":"Exacerbated innate host response to SARS-CoV in aged non-human primates","volume":"6","author":"Smits","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.lfs.2020.118054_bb0080","series-title":"Cytokine Storm and Sepsis Disease Pathogenesis. Seminars in Immunopathology","year":"2017"},{"issue":"6","key":"10.1016\/j.lfs.2020.118054_bb0085","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1440-1843.2006.00942.x","article-title":"Temporal changes in cytokine\/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome","volume":"11","author":"Chien","year":"2006","journal-title":"Respirology"},{"issue":"10223","key":"10.1016\/j.lfs.2020.118054_bb0090","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lfs.2020.118054_bb0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"4","key":"10.1016\/j.lfs.2020.118054_bb0100","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1089\/jir.2014.0227","article-title":"Disease-promoting effects of type I interferons in viral, bacterial, and coinfections","volume":"35","author":"Davidson","year":"2015","journal-title":"J. Interf. Cytokine Res."},{"issue":"8","key":"10.1016\/j.lfs.2020.118054_bb0105","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1164\/rccm.200407-857OC","article-title":"Characterization of cytokine\/chemokine profiles of severe acute respiratory syndrome","volume":"171","author":"Jiang","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2172-6-2","article-title":"Expression profile of immune response genes in patients with severe acute respiratory syndrome","volume":"6","author":"Reghunathan","year":"2005","journal-title":"BMC Immunol."},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.virusres.2007.02.014","article-title":"Human immunopathogenesis of severe acute respiratory syndrome (SARS)","volume":"133","author":"Cameron","year":"2008","journal-title":"Virus Res."},{"key":"10.1016\/j.lfs.2020.118054_bb0120","first-page":"1","article-title":"RIG-I-like receptors: their regulation and roles in RNA sensing","author":"Rehwinkel","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.lfs.2020.118054_bb0125","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1128\/JVI.79.10.6441-6448.2005","article-title":"Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection","volume":"79","author":"Schmitz","year":"2005","journal-title":"J. Virol."},{"issue":"105","key":"10.1016\/j.lfs.2020.118054_bb0130","first-page":"cm1","article-title":"Interleukin-1 (IL-1) pathway","volume":"3","author":"Weber","year":"2010","journal-title":"Sci. Signal."},{"issue":"6","key":"10.1016\/j.lfs.2020.118054_bb0135","first-page":"2757","article-title":"Constitutive and interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene","volume":"10","author":"Isshiki","year":"1990","journal-title":"Mol. Cell. Biol."},{"issue":"11","key":"10.1016\/j.lfs.2020.118054_bb0140","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ncprheum0338","article-title":"Interleukin 6: from bench to bedside","volume":"2","author":"Nishimoto","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"5","key":"10.1016\/j.lfs.2020.118054_bb0145","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat. Immunol."},{"issue":"0","key":"10.1016\/j.lfs.2020.118054_bb0150","first-page":"E005","article-title":"Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia","volume":"43","author":"Chen","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"10.1016\/j.lfs.2020.118054_bb0155","series-title":"Characteristics of Lymphocyte Subsets and Cytokines in Peripheral Blood of 123 Hospitalized Patients With 2019 Novel Coronavirus Pneumonia (NCP)","author":"Wan","year":"2020"},{"issue":"7","key":"10.1016\/j.lfs.2020.118054_bb0160","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1523\/JNEUROSCI.2830-13.2014","article-title":"Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain","volume":"34","author":"Campbell","year":"2014","journal-title":"J. Neurosci."},{"issue":"11","key":"10.1016\/j.lfs.2020.118054_bb0165","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1471-4906(02)02319-0","article-title":"Is selection for TCR affinity a factor in cytokine polarization?","volume":"23","author":"Boyton","year":"2002","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif","year":"2017","journal-title":"Cell Commun Signal"},{"issue":"6","key":"10.1016\/j.lfs.2020.118054_bb0175","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1159\/000508247","article-title":"JAK inhibition as a new treatment strategy for patients with COVID-19","volume":"181","author":"Seif","year":"2020","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"3","key":"10.1016\/j.lfs.2020.118054_bb0180","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1164\/ajrccm\/139.3.682","article-title":"Accumulation of hyaluronan (hyaluronic acid) in the lung in adult respiratory distress syndrome","volume":"139","author":"Hallgren","year":"1989","journal-title":"Am. Rev. Respir. Dis."},{"issue":"3","key":"10.1016\/j.lfs.2020.118054_bb0185","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/biof.1633","article-title":"COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin","volume":"46","author":"Theoharides","year":"2020","journal-title":"Biofactors"},{"issue":"2","key":"10.1016\/j.lfs.2020.118054_bb0190","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jaci.2018.01.034","article-title":"Mast cells signal their importance in health and disease","volume":"142","author":"Olivera","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.lfs.2020.118054_bb0195","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.4049\/jimmunol.178.6.3368","article-title":"Cutting edge: influenza a virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells","volume":"178","author":"Le Goffic","year":"2007","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.lfs.2020.118054_bb0200","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.lfs.2020.118054_bb0205","article-title":"Dysregulation of immune response in patients with COVID-19 in Wuhan, China","author":"Qin","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"10229","key":"10.1016\/j.lfs.2020.118054_bb0210","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0215","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","article-title":"Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors","volume":"9","author":"Han","year":"2020","journal-title":"Emerg Microbes Infect"},{"issue":"5","key":"10.1016\/j.lfs.2020.118054_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/j.lfs.2020.118054_bb0225","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.semarthrit.2013.08.001","article-title":"Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums","volume":"43","author":"Navarro","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.lfs.2020.118054_bb0230","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert. Rev. Clin. Immunol."},{"issue":"20","key":"10.1016\/j.lfs.2020.118054_bb0235","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2020.118054_bb0240","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25964","article-title":"Tocilizumab for the treatment of severe coronavirus disease 2019","author":"Alattar","year":"2020","journal-title":"J. Med. Virol."},{"issue":"7","key":"10.1016\/j.lfs.2020.118054_bb0245","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: a single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J. Med. Virol."},{"issue":"7","key":"10.1016\/j.lfs.2020.118054_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102564","article-title":"Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?","volume":"19","author":"Antinori","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.lfs.2020.118054_bb0255","first-page":"529","article-title":"Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19","volume":"38","author":"Sciascia","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"issue":"7","key":"10.1016\/j.lfs.2020.118054_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102568","article-title":"Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy","volume":"19","author":"Toniati","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"10.1016\/j.lfs.2020.118054_bb0265","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.annonc.2020.03.300","article-title":"Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report","volume":"31","author":"Michot","year":"2020","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"issue":"7","key":"10.1016\/j.lfs.2020.118054_bb0270","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ajh.25833","article-title":"Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab","volume":"95","author":"De Luna","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lfs.2020.118054_bb0275","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25855","article-title":"Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome","author":"Odievre","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lfs.2020.118054_bb0280","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.lfs.2020.118054_bb0285","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000507417","article-title":"A case of novel coronavirus disease 19 in a chronic hemodialysis patient presenting with gastroenteritis and developing severe pulmonary disease","volume":"51","author":"Ferrey","year":"2020","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.lfs.2020.118054_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2020.04.024","article-title":"Use of tocilizumab for COVID-19-induced cytokine release syndrome: a cautionary case report","author":"Radbel","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.lfs.2020.118054_bb0295","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25907","article-title":"Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab","author":"Morrison","year":"2020","journal-title":"J. Med. Virol."},{"issue":"9","key":"10.1016\/j.lfs.2020.118054_bb0300","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/CM9.0000000000000819","article-title":"Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7)","volume":"133","year":"2020","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.lfs.2020.118054_bb0305","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25897","article-title":"Off-label use of tocilizumab in patients with SARS-CoV-2 infection","author":"Di Giambenedetto","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.lfs.2020.118054_bb0310","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2147\/DDDT.S100302","article-title":"Profile of sarilumab and its potential in the treatment of rheumatoid arthritis","volume":"11","author":"Raimondo","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.lfs.2020.118054_bb0315","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.26062","article-title":"COVID-19 pneumonia treated with sarilumab: a clinical series of eight patients","author":"Benucci","year":"2020","journal-title":"J. Med. Virol."},{"issue":"5","key":"10.1016\/j.lfs.2020.118054_bb0320","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/1078-0432.CCR-14-1678","article-title":"FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease","volume":"21","author":"Deisseroth","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2020.118054_bb0325","series-title":"Use of Siltuximab in Patients With COVID-19 Pneumonia Requiring Ventilatory Support","author":"Gritti","year":"2020"},{"key":"10.1016\/j.lfs.2020.118054_bb0330","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2020.118054_bb0335","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","article-title":"Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies","volume":"66","author":"Schulert","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0340","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2796.2010.02313.x","article-title":"Blocking interleukin-1beta in acute and chronic autoinflammatory diseases","volume":"269","author":"Dinarello","year":"2011","journal-title":"J. Intern. Med."},{"issue":"1157","key":"10.1016\/j.lfs.2020.118054_bb0345","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra therapy for non-cancer inflammatory diseases","volume":"9","author":"Cavalli","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.lfs.2020.118054_bb0350","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/acr2.11135","article-title":"Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome","volume":"2","author":"Monteagudo","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.lfs.2020.118054_bb0355","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217706","article-title":"Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series","author":"Aouba","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.lfs.2020.118054_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.05.002","article-title":"Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease","author":"Pontali","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.lfs.2020.118054_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2020.05.007","article-title":"Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis","author":"Dimopoulos","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"6","key":"10.1016\/j.lfs.2020.118054_bb0370","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.lfs.2020.118054_bb0375","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217562","article-title":"Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19","author":"Moutsopoulos","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.lfs.2020.118054_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30167-3","article-title":"Canakinumab in a subgroup of patients with COVID-19","author":"Ucciferri","year":"2020","journal-title":"The Lancet Rheumatology"},{"issue":"3","key":"10.1016\/j.lfs.2020.118054_bb0385","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jmii.2020.03.005","article-title":"TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor fedratinib","volume":"53","author":"Wu","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"issue":"7","key":"10.1016\/j.lfs.2020.118054_bb0390","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","article-title":"Baricitinib: a review in rheumatoid arthritis","volume":"78","author":"Al-Salama","year":"2018","journal-title":"Drugs"},{"issue":"10223","key":"10.1016\/j.lfs.2020.118054_bb0395","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lfs.2020.118054_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102523","article-title":"COVID-19 infection and rheumatoid arthritis: faraway, so close!","volume":"19","author":"Favalli","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.lfs.2020.118054_bb0405","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2213-2600(20)30216-2","article-title":"COVID-19 cytokine storm: the interplay between inflammation and coagulation","volume":"8","author":"Jose","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lfs.2020.118054_bb0410","article-title":"Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact","author":"Cantini","year":"2020","journal-title":"J. Inf. Secur."},{"issue":"2","key":"10.1016\/j.lfs.2020.118054_bb0415","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nrd3652","article-title":"Ruxolitinib","volume":"11","author":"Mesa","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.lfs.2020.118054_bb0420","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"The Lancet Haematology"},{"issue":"15","key":"10.1016\/j.lfs.2020.118054_bb0425","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40265-019-01205-x","article-title":"Fedratinib: first approval","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0430","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5935\/0004-2749.20190002","article-title":"Evaluation of toxic retinopathy caused by antimalarial medications with spectral domain optical coherence tomography","volume":"82","author":"Cabral","year":"2019","journal-title":"Arq. Bras. Oftalmol."},{"issue":"12","key":"10.1016\/j.lfs.2020.118054_bb0435","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41584-018-0111-8","article-title":"Hydroxychloroquine retinopathy - implications of research advances for rheumatology care","volume":"14","author":"Jorge","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118054_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"3","key":"10.1016\/j.lfs.2020.118054_bb0445","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0450","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-017-1393-y","article-title":"Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling","volume":"19","author":"Wu","year":"2017","journal-title":"Arthritis research & therapy"},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0455","first-page":"55","article-title":"Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells","volume":"24","author":"van den Borne","year":"1997","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.lfs.2020.118054_bb0460","first-page":"m1335","article-title":"Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence","volume":"369","author":"Lenzer","year":"2020","journal-title":"BMJ (Clinical research ed)"},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0465","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12981-017-0166-7","article-title":"Preventing HIV infection without targeting the virus: how reducing HIV target cells at the genital tract is a new approach to HIV prevention","volume":"14","author":"Lajoie","year":"2017","journal-title":"AIDS Res. Ther."},{"issue":"4","key":"10.1016\/j.lfs.2020.118054_bb0470","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cbf.3182","article-title":"Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity","volume":"34","author":"Akpovwa","year":"2016","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.lfs.2020.118054_bb0475","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"issue":"3","key":"10.1016\/j.lfs.2020.118054_bb0480","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.lfs.2020.118054_bb0485","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2020.118054_bb0490","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.virusres.2014.11.021","article-title":"Host cell proteases: critical determinants of coronavirus tropism and pathogenesis","volume":"202","author":"Millet","year":"2015","journal-title":"Virus Res."},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0495","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.293","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","author":"Al-Bari","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"issue":"2","key":"10.1016\/j.lfs.2020.118054_bb0500","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.antiviral.2007.10.011","article-title":"Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK","volume":"77","author":"Kono","year":"2008","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0505","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Bioscience trends"},{"issue":"6","key":"10.1016\/j.lfs.2020.118054_bb0510","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/art.10307","article-title":"Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis","volume":"46","author":"Munster","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.lfs.2020.118054_bb0515","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/gut.35.4.569","article-title":"Fulminant hepatic failure secondary to hydroxychloroquine","volume":"35","author":"Makin","year":"1994","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.lfs.2020.118054_bb0520","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/15563650500514558","article-title":"Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia","volume":"44","author":"Chen","year":"2006","journal-title":"Clinical toxicology (Philadelphia, Pa)"},{"issue":"2","key":"10.1016\/j.lfs.2020.118054_bb0525","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/j.ijcard.2007.04.055","article-title":"Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine","volume":"127","author":"Stas","year":"2008","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.lfs.2020.118054_bb0530","first-page":"1","article-title":"Chloroquine-induced QTc prolongation in COVID-19 patients","author":"van den Broek","year":"2020","journal-title":"Neth Heart J"},{"issue":"12","key":"10.1016\/j.lfs.2020.118054_bb0535","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/j.1540-8159.2007.00912.x","article-title":"Azithromycin-induced torsade de pointes","volume":"30","author":"Huang","year":"2007","journal-title":"Pacing and clinical electrophysiology: PACE"},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0540","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3748\/wjg.15.25","article-title":"Gastroparesis: current diagnostic challenges and management considerations","volume":"15","author":"Waseem","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.lfs.2020.118054_bb0545","doi-asserted-by":"crossref","first-page":"116972","DOI":"10.1016\/j.jns.2020.116972","article-title":"Hydroxychloroquine\/chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: a primum non nocere dilemma","volume":"415","author":"Chevalier","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.lfs.2020.118054_bb0550","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25868","article-title":"The emergence of methemoglobinemia amidst the COVID-19 pandemic","author":"Naymagon","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lfs.2020.118054_bb0555","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","volume":"57","author":"Cortegiani","year":"2020","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.lfs.2020.118054_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2020.e00778","article-title":"SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: implications for prophylaxis","volume":"20","author":"Dousa","year":"2020","journal-title":"IDCases"},{"key":"10.1016\/j.lfs.2020.118054_bb0565","first-page":"m1849","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"BMJ (Clinical research ed)"},{"issue":"4","key":"10.1016\/j.lfs.2020.118054_bb0570","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.lfs.2020.118054_bb0575","unstructured":"Administration USFaD. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or. accessed 26 June, 2020."},{"issue":"17","key":"10.1016\/j.lfs.2020.118054_bb0580","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20174241","article-title":"Mast cell responses to viruses and pathogen products","volume":"20","author":"Marshall","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.lfs.2020.118054_bb0585","first-page":"193","article-title":"Role of mast cells in innate and adaptive immunity","volume":"26","author":"Tete","year":"2012","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.lfs.2020.118054_bb0590","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fimmu.2015.00238","article-title":"Mast cells and influenza a virus: association with allergic responses and beyond","volume":"6","author":"Graham","year":"2015","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0595","article-title":"Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy","volume":"34","author":"Kritas","year":"2020","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.lfs.2020.118054_bb0600","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00481","article-title":"Contributions of mast cells and vasoactive products, leukotrienes and chymase, to dengue virus-induced vascular leakage","volume":"2","author":"St John","year":"2013","journal-title":"Elife"},{"issue":"6","key":"10.1016\/j.lfs.2020.118054_bb0605","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1128\/JVI.06053-11","article-title":"Mast cell-induced lung injury in mice infected with H5N1 influenza virus","volume":"86","author":"Hu","year":"2012","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.lfs.2020.118054_bb0610","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2500\/108854189778960135","article-title":"Ocular, nasal and oral cromolyn sodium in the management of non-asthmatic allergic problems","volume":"10","author":"Spector","year":"1989","journal-title":"Allergy proceedings: the official journal of regional and state allergy societies"},{"key":"10.1016\/j.lfs.2020.118054_bb0615","series-title":"Assisted Ventilation of the Neonate","first-page":"366","article-title":"Pharmacologic therapies IV","volume":"vol. e5","author":"Kandasamy","year":"2017"},{"key":"10.1016\/j.lfs.2020.118054_bb0620","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fphar.2017.00827","article-title":"The anti-allergic cromones: past, present, and future","volume":"8","author":"Sinniah","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0625","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/irv.12334","article-title":"The therapeutic effects of sodium cromoglycate against influenza A virus H5N1 in mice","volume":"10","author":"Han","year":"2016","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.lfs.2020.118054_bb0630","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.lfs.2020.118054_bb0635","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.bbamem.2010.05.006","article-title":"Viral proteins function as ion channels","volume":"1808","author":"Wang","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.lfs.2020.118054_bb0640","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1099\/jgv.0.000712","article-title":"Viral dependence on cellular ion channels - an emerging anti-viral target?","volume":"98","author":"Hover","year":"2017","journal-title":"The Journal of general virology"},{"issue":"5 Pt 2","key":"10.1016\/j.lfs.2020.118054_bb0645","article-title":"Chloride transport and the actions of nedocromil sodium and cromolyn sodium in asthma","volume":"98","author":"Alton","year":"1996","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.lfs.2020.118054_bb0650","series-title":"Pharmacology and Therapeutics for Dentistry","first-page":"392","article-title":"Drugs acting on the respiratory system","author":"Gregson","year":"2017"},{"issue":"4","key":"10.1016\/j.lfs.2020.118054_bb0655","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1074\/jbc.M114.586602","article-title":"A food and drug administration-approved asthma therapeutic agent impacts amyloid beta in the brain in a transgenic model of Alzheimer disease","volume":"290","author":"Hori","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.lfs.2020.118054_bb0660","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s40261-017-0549-5","article-title":"Pharmacokinetics of cromolyn and ibuprofen in healthy elderly volunteers","volume":"37","author":"Brazier","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"3","key":"10.1016\/j.lfs.2020.118054_bb0665","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3382\/ps.2008-00468","article-title":"Evidence for a role of mast cells in the mucosal injury induced by Newcastle disease virus","volume":"88","author":"Sun","year":"2009","journal-title":"Poult. Sci."},{"issue":"20","key":"10.1016\/j.lfs.2020.118054_bb0670","doi-asserted-by":"crossref","first-page":"11334","DOI":"10.1128\/JVI.78.20.11334-11339.2004","article-title":"Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells","volume":"78","author":"Yi","year":"2004","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.lfs.2020.118054_bb0675","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1039\/C6FO01825D","article-title":"A structural mechanism of flavonoids in inhibiting serine proteases","volume":"8","author":"Xue","year":"2017","journal-title":"Food Funct."},{"issue":"24","key":"10.1016\/j.lfs.2020.118054_bb0680","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1016\/j.bmc.2006.09.014","article-title":"Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features","volume":"14","author":"Chen","year":"2006","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0685","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2249.2004.02415.x","article-title":"Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome","volume":"136","author":"Wong","year":"2004","journal-title":"Clin. Exp. Immunol."},{"issue":"10234","key":"10.1016\/j.lfs.2020.118054_bb0690","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","article-title":"Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed","volume":"395","author":"Feldmann","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lfs.2020.118054_bb0695","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1084\/jem.170.5.1627","article-title":"Antibodies to cachectin\/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia","volume":"170","author":"Fong","year":"1989","journal-title":"J. Exp. Med."},{"issue":"8657","key":"10.1016\/j.lfs.2020.118054_bb0700","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","article-title":"Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis","volume":"2","author":"Brennan","year":"1989","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.lfs.2020.118054_bb0705","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","article-title":"Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis","volume":"163","author":"Charles","year":"1999","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0710","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12918-016-0336-6","article-title":"The effect of inhibition of PP1 and TNFalpha signaling on pathogenesis of SARS coronavirus","volume":"10","author":"McDermott","year":"2016","journal-title":"BMC Syst. Biol."},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0715","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1185\/030079903125002757","article-title":"TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection","volume":"20","author":"Tobinick","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.lfs.2020.118054_bb0720","series-title":"Pediatric Pulmonology","first-page":"95","article-title":"Asthma","author":"Veler","year":"2005"},{"key":"10.1016\/j.lfs.2020.118054_bb0725","series-title":"Middleton\u2019s Allergy","first-page":"1602","article-title":"100 - antileukotriene therapy in asthma","author":"Wenzel","year":"2014"},{"issue":"2","key":"10.1016\/j.lfs.2020.118054_bb0730","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11882-007-0010-6","article-title":"Leukotriene synthesis inhibitors versus antagonists: the pros and cons","volume":"7","author":"Steinke","year":"2007","journal-title":"Curr Allergy Asthma Rep"},{"issue":"4","key":"10.1016\/j.lfs.2020.118054_bb0735","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/vim.2011.0099","article-title":"SARS-CoV regulates immune function-related gene expression in human monocytic cells","volume":"25","author":"Hu","year":"2012","journal-title":"Viral Immunol."},{"key":"10.1016\/j.lfs.2020.118054_bb0740","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.3389\/fmicb.2019.03079","article-title":"Montelukast, an anti-asthmatic drug, inhibits Zika virus infection by disrupting viral integrity","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.lfs.2020.118054_bb0745","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0076-6879(94)44008-5","article-title":"Tryptase: a mast cell serine protease","volume":"244","author":"Schwartz","year":"1994","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.lfs.2020.118054_bb0750","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","article-title":"Protease inhibitors targeting coronavirus and filovirus entry","volume":"116","author":"Zhou","year":"2015","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0755","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"issue":"Suppl. 2","key":"10.1016\/j.lfs.2020.118054_bb0760","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2036.1996.22164025.x","article-title":"Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies","volume":"10","author":"Brattsand","year":"1996","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"10225","key":"10.1016\/j.lfs.2020.118054_bb0765","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","article-title":"On the use of corticosteroids for 2019-nCoV pneumonia","volume":"395","author":"Shang","year":"2020","journal-title":"Lancet"},{"issue":"10223","key":"10.1016\/j.lfs.2020.118054_bb0770","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0775","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection risk and safety of corticosteroid use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."},{"issue":"4","key":"10.1016\/j.lfs.2020.118054_bb0780","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jcv.2004.07.006","article-title":"Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients","volume":"31","author":"Lee","year":"2004","journal-title":"J. Clin. Virol."},{"issue":"6","key":"10.1016\/j.lfs.2020.118054_bb0785","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1378\/chest.129.6.1441","article-title":"Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience","volume":"129","author":"Chen","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.lfs.2020.118054_bb0790","series-title":"Effect of Dexamethasone in Hospitalized Patients With COVID-19: Preliminary Report","author":"Horby","year":"2020"},{"key":"10.1016\/j.lfs.2020.118054_bb0795","unstructured":"World Health Organization. WHO welcomes preliminary results about dexamethasone use in treating critically ill COVID-19 patients. https:\/\/www.who.int\/news-room\/detail\/16-06-2020-who-welcomes-preliminary-results-about-dexamethasone-use-in-treating-critically-ill-covid-19-patients. accessed 26 June, 2020."},{"key":"10.1016\/j.lfs.2020.118054_bb0800","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa601","article-title":"Early short course corticosteroids in hospitalized patients with COVID-19","author":"Fadel","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.lfs.2020.118054_bb0805","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","article-title":"Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial","volume":"8","author":"Villar","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"1\u20132","key":"10.1016\/j.lfs.2020.118054_bb0810","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbamem.2004.01.006","article-title":"Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage","volume":"1663","author":"Cevc","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.lfs.2020.118054_bb0815","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/cmi.2015.74","article-title":"The cytokine storm of severe influenza and development of immunomodulatory therapy","volume":"13","author":"Liu","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.lfs.2020.118054_bb0820","doi-asserted-by":"crossref","DOI":"10.1172\/JCI139642","article-title":"Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists","author":"Konig","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"7735","key":"10.1016\/j.lfs.2020.118054_bb0825","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","article-title":"Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome","volume":"564","author":"Staedtke","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.lfs.2020.118054_bb0830","doi-asserted-by":"crossref","DOI":"10.3390\/nu12040988","article-title":"Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths","volume":"12","author":"Grant","year":"2020","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.lfs.2020.118054_bb0835","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175517","article-title":"Vitamin D deficiency is associated with IL-6 levels and monocyte activation in HIV-infected persons","volume":"12","author":"Manion","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2020.118054_bb0840","series-title":"The Possible Role of Vitamin D in Suppressing Cytokine Storm and Associated Mortality in COVID-19 Patients","author":"Daneshkhah","year":"2020"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520308055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320520308055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T21:21:53Z","timestamp":1765228913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320520308055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":168,"alternative-id":["S0024320520308055"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118054","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tackling the cytokine storm in COVID-19, challenges and hopes","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2020.118054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"118054"}}